

# Cohort – The Kungsholmen projekt

<https://www.neurodegenerationresearch.eu/survey/cohort-the-kungsholmen-projekt/>

## Title of the cohort

Cohort – The Kungsholmen projekt

## Acronym for cohort

## Name of Principal Investigator

Title Professor

First name Laura

Last name Fratiglioni

## Address of institution where award is held

Institution Aging Research Center

Street Address

City Stockholm

Postcode 113 30

## Country

- Sweden

## Website

[www.kungsholmenproject.se](http://www.kungsholmenproject.se)

## Contact email

[email protected]

## Funding source

### 1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer's disease and other dementias
- Neurodegenerative disease in general

### When studies on the above condition(s) are expected to become possible

- Already possible

### 2a. Stated aim of the cohort

The aim is to detect occurrence and determinants of dementia and Alzheimer.

### 2b. Features distinguishing this cohort from other population cohorts

#### 3a. i) Number of publications that involve use of cohort to date

400

#### 3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)

**3b. Publication list/link to where data or publications are accessible (if available)**

www.kungsholmen.se

**3c. Information (i.e. research findings) expected to be gained from the population cohort**

**4a. Study criteria: age range of participants at recruitment**

Age in years from: 75+

To ('until death' if applicable): until death

**4b. Study criteria: inclusion criteria**

75+ years living in Kungsholmen area, Stockholm at 1987

**4c. Study criteria: exclusion criteria**

No

**5. Size of the cohort (i.e. number of participants enrolled)**

- 1,000 – 5,000 participants

**6a. Measures used to characterise participants**

Social, medical and functional characterise

**6b. Additional measures for participants with a clinical disorder**

Yes

**6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)**

All cronic disorders, functional impairoment mortality

**7. Study design**

- Longitudinal

**8. Cases matched by**

- Other health assessment (specify) / N/A
- Not relevant

**9a. Does the study include a specialised subset of control participants**

- No

**9b. If yes, description of specialised subset of control participants**

**10a. i) Data collection start date**

31-01-1987

**10a. ii) Data collection end date**

31-12-2000

**10a iii) Data collection for this study is**

- Data analysis ongoing
- Closed to new patients

**10b. Plans to continue the cohort study beyond the current projected end date**

- Yes – funding applied for

**11. Data collected**

- Only through the study
- Through links to medical records

**12. System in place to enable re-contact with patients for future studies**

- No

**13a. Format and availability of data stored in a database**

Yes/No % available

Data summarised in database

Database is web-based

Database on spreadsheet      yes      100

Database is on paper          yes      100

Other (specify)

**Language used:**

Swedish

**13b. Format and availability of data held as individual records**

Yes/No % available

Data held as individual records

Data is web-based

Data held on computer based records      yes      100

Data held on cards

Other (specify)

**Language used:**

Swedish

**14a. Are data available to other groups**

Yes

**14b. Access policy/mechanisms for access if data are available to other groups**

- Apply to PI or co-ordinator at resource
- Resource has own ethics approval so usually no need for separate external ethics approval

**15. Data sharing policy specified as a condition of use**

- No policy exists

**16a. Are tissues/samples/DNA available to other groups**

Yes

**16b. i) Description of available tissues/samples/DNA**

- Living donors: blood
- Living donors: blood derivatives
- Living donors: DNA

**16b. ii) Form available tissues/samples/DNA are supplied in**

- Secondary samples: plasma

**16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data**

Yes

**17. Is information on biological characteristics available to other groups**

- Yes, for all the cohort